{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:59:19Z","timestamp":1779292759257,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Research Special Fund for Public Welfare Industry of Health","award":["201202004"],"award-info":[{"award-number":["201202004"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373188"],"award-info":[{"award-number":["81373188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671618"],"award-info":[{"award-number":["81671618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital Health Research and Development of Special Fund","award":["2014-1-4011"],"award-info":[{"award-number":["2014-1-4011"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["2017-I2M-3-001"],"award-info":[{"award-number":["2017-I2M-3-001"]}]},{"name":"CAMS Initiative for Innovative Medicine","award":["2017-I2M-B&R-01"],"award-info":[{"award-number":["2017-I2M-B&R-01"]}]},{"name":"National Key Research and Development Program of China","award":["2016YFC0903900"],"award-info":[{"award-number":["2016YFC0903900"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jns.2018.12.040","type":"journal-article","created":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:15:28Z","timestamp":1546301728000},"page":"123-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Myositis-specific autoantibodies in dermatomyositis\/polymyositis with interstitial lung disease"],"prefix":"10.1016","volume":"397","author":[{"given":"Liubing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2018.12.040_bb0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jns.2018.12.040_bb0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2018.12.040_bb0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.12.040_bb0020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.12.040_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jns.2018.12.040_bb0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2036.2009.04190.x","article-title":"Review article: the gastrointestinal complications of myositis","volume":"31","author":"Ebert","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2018.12.040_bb0035","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/gut.52.4.471","article-title":"Biomechanics, diagnosis, and treatment outcome in inflammatory myopathy presenting as oropharyngeal dysphagia","volume":"52","author":"Williams","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jns.2018.12.040_bb0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-199905000-00001","article-title":"Influence of age on characteristics of polymyositis and dermatomyositis in adults","volume":"78","author":"Marie","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jns.2018.12.040_bb0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/art.1780260804","article-title":"Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis","volume":"26","author":"de Merieux","year":"1983","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2018.12.040_bb0050","first-page":"683","article-title":"Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study","volume":"34","author":"Zhong","year":"2017","journal-title":"Int. J. Cardiovasc. Imag."},{"key":"10.1016\/j.jns.2018.12.040_bb0055","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3899\/jrheum.161311","article-title":"Subclinical Cardiac Dysfunction in Polymyositis and Dermatomyositis: a Speckle-tracking Case-control Study","volume":"44","author":"Guerra","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jns.2018.12.040_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000291","article-title":"Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies","volume":"2","author":"Schwartz","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jns.2018.12.040_bb0065","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.autrev.2016.01.015","article-title":"Cardiac involvement in polymyositis and dermatomyositis","volume":"15","author":"Danieli","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2018.12.040_bb0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0034-1371528","article-title":"Pulmonary manifestations of polymyositis\/dermatomyositis","volume":"35","author":"Hallowell","year":"2014","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.jns.2018.12.040_bb0075","first-page":"1336","article-title":"Pulmonary involvement in polymyositis and in dermatomyositis","volume":"25","author":"Marie","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jns.2018.12.040_bb0080","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.bor.0000179949.65895.53","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"17","author":"Fathi","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jns.2018.12.040_bb0085","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2018.12.040_bb0090","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2018.12.040_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00403-016-1704-1","article-title":"Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets","volume":"309","author":"Merlo","year":"2017","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.jns.2018.12.040_bb0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.jns.2018.12.040_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/joim.12524","article-title":"Diagnosis and classification of idiopathic inflammatory myopathies","volume":"280","author":"Lundberg","year":"2016","journal-title":"J. Intern. Med."},{"issue":"2017","key":"10.1016\/j.jns.2018.12.040_bb0110","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jns.2018.12.040_bb0115","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Group on classification criteria for Sjogren's, classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jns.2018.12.040_bb0120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2018.12.040_bb0125","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2018.12.040_bb0130","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2018.12.040_bb0135","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2018.12.040_bb0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jns.2018.12.040_bb0145","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jns.2018.12.040_bb0150","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jns.2018.12.040_bb0155","doi-asserted-by":"crossref","first-page":"26552","DOI":"10.18632\/oncotarget.15716","article-title":"Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jns.2018.12.040_bb0160","doi-asserted-by":"crossref","first-page":"76129","DOI":"10.18632\/oncotarget.19050","article-title":"Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jns.2018.12.040_bb0165","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","article-title":"The prognostic value of HRCT in myositis-associated interstitial lung disease","volume":"107","author":"Tanizawa","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.jns.2018.12.040_bb0170","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2014-eular.2390","article-title":"Significance of relationship between anti-tif1 autoantibodies profiles and cancer-associated Myositis","volume":"73","author":"Lu","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jns.2018.12.040_bb0175","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jns.2018.12.040_bb0180","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and Systemic Findings Associated with Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jns.2018.12.040_bb0185","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2018.12.040_bb0190","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jns.2018.12.040_bb0195","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/pgmj.2009.089656","article-title":"Diagnostic utility of anti-Ro52 detection in systemic autoimmunity","volume":"86","author":"Dugar","year":"2010","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jns.2018.12.040_bb0200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/jaut.1998.0265","article-title":"The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies","volume":"12","author":"Frank","year":"1999","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jns.2018.12.040_bb0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jns.2018.12.040_bb0210","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jns.2018.12.040_bb0215","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2474-11-223","article-title":"Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis","volume":"11","author":"Kang","year":"2010","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.jns.2018.12.040_bb0220","article-title":"Hyperacute muscle weakness in an unusual coexistence of antisignal recognition particle and anti-Mi-2 antibodies","volume":"2017","author":"Akintayo","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.jns.2018.12.040_bb0225","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/rheumatology\/kes073","article-title":"Clinical features of anti-TIF1-alpha antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-gamma or anti-Mi-2 autoantibodies","volume":"51","author":"Muro","year":"2012","journal-title":"Rheumatology (Oxford)"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18305355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18305355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T07:08:21Z","timestamp":1605942501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18305355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":45,"alternative-id":["S0022510X18305355"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.12.040","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myositis-specific autoantibodies in dermatomyositis\/polymyositis with interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}